^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microbiome modulator

    Related drugs:
    9d
    R-3750-01-LU: A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Rise Therapeutics LLC | Trial completion date: Dec 2027 --> Dec 2028 | Initiation date: Nov 2025 --> Sep 2026 | Trial primary completion date: Apr 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    9d
    R-3750 in Patients With Mild to Moderate Ulcerative Colitis (clinicaltrials.gov)
    P1, N=36, Recruiting, Rise Therapeutics LLC | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    10d
    ROAR: REBYOTA™ Prospective Registry (clinicaltrials.gov)
    P=N/A, N=145, Completed, Ferring Pharmaceuticals | Recruiting --> Completed | Trial completion date: Apr 2026 --> Aug 2025 | Trial primary completion date: Feb 2026 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    23d
    A Phase 1b Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple Dose Safety and Tolerability Study of Daily Dosing of BL-001 for 12 Weeks in Adults with Obesity (ACTRN12626000061336)
    P1, N=48, Not yet recruiting, Bloom Science Australia Pty Ltd
    New P1 trial
    2ms
    StarFish-UC: Confirmatory Clinical Study in Active Ulcerative Colitis (clinicaltrials.gov)
    P2, N=204, Not yet recruiting, MRM Health NV
    New P2 trial
    2ms
    Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=8, Terminated, University of Chicago | Trial completion date: Nov 2027 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2027 --> Jul 2025; Drug supply no longer available.
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • EDP1503
    3ms
    adored: Allergic Disease Onset Prevention Study (clinicaltrials.gov)
    P1/2, N=283, Completed, Siolta Therapeutics, Inc. | Active, not recruiting --> Completed
    Trial completion
    4ms
    A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC (clinicaltrials.gov)
    P2, N=87, Recruiting, LISCure Biosciences | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    4ms
    Medicinal Cannabis for Endometriosis: The Gut Microbiome (ACTRN12624000828527)
    P2, N=28, Not yet recruiting, Western Sydney University | N=42 --> 28
    Enrollment change
    4ms
    KAN-004 for Immune-Related Diarrhea or Colitis (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Centre hospitalier de l'Université de Montréal (CHUM)
    New P1 trial
    5ms
    Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis (clinicaltrials.gov)
    P4, N=100, Recruiting, Mahidol University
    New P4 trial
    5ms
    Two microbiome metabolites compete for tRNA modification to impact mammalian cell proliferation and translation quality control. (PubMed, Nat Cell Biol)
    The microbiome affects eukaryotic host cells via many metabolites, including the well-studied queuine as substrate for host tRNA queuosine modification...We identify the endoplasmic reticulum-localized inositol-requiring enzyme 1 (IRE1) ribonuclease as the enzyme responsible for the selective degradation of preQ1-modified tRNAs on translating ribosomes. Our results identify two microbial metabolites competing for host tRNA modification, which elicits translation quality control and impacts cell proliferation.
    Journal
    |
    ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1)